Instil Bio Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Hello, everybody. This is Bronson Crouch, the CEO of Instil Bio. I'm joined with Zach Roberts, our Chief Medical Officer. For those who are just getting familiar with us, we are a company developing TIL as both a therapy and a platform to treat solid tumor cancers. TILs are (inaudible) population of T cells that have experience in the tumor and naturally target multiple antigens cells important for the treatment of solid tumor cancers. Our experience in developing these therapies is experience is extensive. We the majority of our team having worked together previously in developing and launching commercially approved cell therapies. This year, we've been again enrolling our ITIL-168 Phase II clinical trial design with registration attempt. And planned approval in 2023. First half Of 2022 next year, we'll begin with ITIL-168 trials forward or additional indications, innovating on the TIL platform our next-generation CoStAR program, we'll initiate its first local trial in the first half of '22. We are committed to manufacturing in rolling our own destiny,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
